Catalyst Biosciences Inc (CBIO)

NASDAQ
0.504
-0.010(-1.91%)
After Hours
0.504
0.000(0.00%)
- Real-time Data
  • Volume:
    291,211
  • Day's Range:
    0.504 - 0.512
  • 52 wk Range:
    0.350 - 4.210
High dividend Yield

Dividend yield shows how much a company pays its shareholders in dividends annually per dollar invested. It reflects how much an investor will earn aside from any capital gains in the stock.

CBIO Overview

Prev. Close
0.514
Day's Range
0.504-0.512
Revenue
6.66M
Open
0.505
52 wk Range
0.35-4.21
EPS
-0.269
Volume
291,211
Market Cap
15.86M
Dividend (Yield)
1.43
(283.73%)
Average Vol. (3m)
699,717
P/E Ratio
-7.24
Beta
1.35
1-Year Change
-87.59%
Shares Outstanding
31,477,053
Next Earnings Date
Nov 10, 2022
What is your sentiment on Catalyst Biosciences?
or
Market is currently closed. Voting is open during market hours.

Catalyst Biosciences Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Catalyst Biosciences Inc Analysis

Catalyst Biosciences Inc Company Profile

Catalyst Biosciences Inc Company Profile

Employees
56

Catalyst Biosciences, Inc. is a research and clinical development biopharmaceutical company. The Company is focused on protease therapeutics to address unmet medical needs in disorders of the complement and coagulation systems. The Company's product candidates consist of the coagulation-related assets marzeptacog alfa (activated) (MarzAA), dalcinonacog alfa (DalcA), and CB 2679d-GT. The Company's product MarzAA is a subcutaneously (SQ) administered next generation engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding and prophylaxis in subjects with rare bleeding disorders. The Company's DalcA is a next generation SQ Factor IX product candidate for the prophylactic treatment of individuals with hemophilia B. Its CB 2679d-GT is an Adeno-associated virus (AAV)-based gene therapy construct harboring the DalcA sequence. The Company's SQ product candidates demonstrate a prolonged duration of activity enabling them to provide continuous therapeutic levels.

Read More

Analyst Price Target

Average15.500 (+2975.40% Upside)
High16
Low15
Price0.504
No. of Analysts2
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellSellStrong SellSellStrong Sell
Technical IndicatorsSellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • needs better leadership
    0
    • RDGL 0.125 By 1/16/2021 FDA will provide a final decision to grant or deny their request for breakthrough designation.
      0
      • hope that in long term it will rise
        0
        • Phase 1/2 completion of dosing announced June 14, 2017 with data due by the end of September.. Data will be excellent! The stock will rock once again!
          0
          • To holders of CBIO: Patience will pay off. Between now and December we should have a major event that would restore the fair price to this stock.
            0
            • Catalyst Biosciences Announces Issuance of Asia Patents Covering Factor IX Hemophilia Program. . 8:01 am ET September 11, 2017 (Globe Newswire) Print
              0
              • CBIO is warming up to something. Maybe good news is in the way. I feel something good is coming
                0
                • why are you selling your shares cheep. Some one is accumulating for the big day.
                  0
                  • Watch out for $CBIO as secondary offering lock-up expires tomorrow 7/6/17
                    0
                    • Something I read from an analyst opinion column today about this . . This is a great news for $CBIO for being able to partner with "ISU Abxis"ISU Abxis is the beggest Biotech ion Korea with annual revenue of $30B.. Furthermore, they are doing some fantastic blood cancer work. If they agreed to $CBIO data, that means something....
                      0